You just read:

Shire Announces EMA Validation of Veyvondi[TM] [Von Willebrand Factor (Recombinant)] Marketing Authorization Application for Treatment of Von Willebrand Disease

News provided by

Shire plc

Jun 22, 2017, 01:00 ET